drugset
drugset / Trial / NCT02329743

Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery

NCT02329743 ↗

Phase 2 Completed 256 enrolled A.T. Resolve SARL
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to assess the efficacy and safety of 2 concentrations of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of ocular inflammation and pain in subjects undergoing cataract surgery.

Timeline

Start
2014-12
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject NAVAMEPENT Small molecule 0.05 % Topical
Subject NAVAMEPENT Small molecule 0.1 % Topical

Indications

cataract